4//SEC Filing
Astor Andrew 4
Accession 0000914190-19-000510
CIK 0001196298other
Filed
Dec 17, 7:00 PM ET
Accepted
Dec 18, 5:14 PM ET
Size
15.9 KB
Accession
0000914190-19-000510
Insider Transaction Report
Form 4
NEPHROS INCNEPH
Astor Andrew
Chief Financial Officer
Transactions
- Award
Stock Option (right to buy)
2019-12-16+20,000→ 20,000 totalExercise: $8.30Exp: 2029-12-16→ Common Stock (20,000 underlying) - Award
Common Stock
2019-12-16+6,848→ 68,308 total
Holdings
- 22,223
Stock Option (right to buy)
Exercise: $5.85Exp: 2028-12-19→ Common Stock (22,223 underlying) - 5,556
Stock Option (right to buy)
Exercise: $4.50Exp: 2027-12-20→ Common Stock (5,556 underlying) - 14,815
Warrants (right to buy)
Exercise: $2.70From: 2017-03-17Exp: 2022-03-17→ Common Stock (14,815 underlying) - 45,079
Stock Option (right to buy)
Exercise: $4.14Exp: 2027-02-13→ Common Stock (45,079 underlying) - 32,567
Stock Option (right to buy)
Exercise: $2.64Exp: 2027-05-01→ Common Stock (32,567 underlying)
Footnotes (6)
- [F1]On December 16, 2019, the Company granted 6,848 shares of restricted stock (the "Restricted Stock") to the Reporting Person in lieu of a cash bonus. The Restricted Stock was granted under the Company's 2015 Equity Incentive Plan. The Restricted Stock vests six months following the grant date.
- [F2]On 2/13/17, the Reporting Person was granted an option to purchase up to 64,399 shares of common stock of the Company. Options to purchase 8,049 shares vested on 2/13/18; options to purchase 24,150 shares vest quarterly in 12 equal amounts commencing on 5/13/18; options to purchase 12,880 shares vested upon approval of listing of the Company's common stock on the Nasdaq Stock Market; options to purchase 6,440 shares will vest, if ever, on 2/1 following the Company's first completed fiscal year in which annual revenue exceeds $6,000,000; and options to purchase 12,880 shares will vest, if ever, on 2/1 following the Company's first completed fiscal year in which annual revenue exceeds $10,000,000.
- [F3]On 5/1/17, the Reporting Person was granted an option to purchase up to 46,525 shares of common stock of the Company. Options to purchase 5,815 shares vested on 5/1/18; options to purchase 17,447 shares vest quarterly in 12 equal amounts commencing on 7/1/18; options to purchase 4,655 shares will vest, if ever, on 2/1 following the Company's first completed fiscal year in which annual revenue exceeds $6,000,000; options to purchase 9,305 shares will vest, if ever, on 2/1 following the Company's first completed fiscal year in which annual revenue exceeds $10,000,000; and options to purchase 9,305 shares vested upon approval of listing of the Company's common stock on the Nasdaq Stock Market.
- [F4]On 12/20/17, the Reporting Person was granted an option to purchase 5,556 shares of common stock of the Company. Options to purchase 1,389 shares vested on 12/20/18 and options to purchase 4,167 shares vest quarterly in 12 equal amounts commencing on 3/20/19.
- [F5]On 12/19/18, the Reporting Person was granted an option to purchase 22,223 shares of common stock of the Company. Options to purchase 5,555 shares vest on 12/19/19 and options to purchase 16,668 shares vest quarterly in 12 equal amounts commencing on 3/19/20.
- [F6]On 12/16/19, the Reporting Person was granted an option to purchase 20,000 shares of common stock of the Company. Options to purchase 5,000 shares vest on 12/16/20 and options to purchase 15,000 shares vest quarterly in 12 equal amounts commencing on 3/16/21.
Documents
Issuer
NEPHROS INC
CIK 0001196298
Entity typeother
Related Parties
1- filerCIK 0001698052
Filing Metadata
- Form type
- 4
- Filed
- Dec 17, 7:00 PM ET
- Accepted
- Dec 18, 5:14 PM ET
- Size
- 15.9 KB